TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults aged 18 years or older~2. Documented diagnosis of FCD~3. Evidence of central corneal edema, in at least one eye, at the Screening and Baseline Visit, in the eligible eye(s)~4. Reduced BCVA secondary to central corneal edema, at Screening and Baseline, in the eligible eye(s)~Exclusion Criteria:~1. FCD so advanced that, in the opinion of the Investigator, surgery would likely be required in the study eligible eye(s) within the study period~2. Clinically significant ocular disease (other than FCD) or trauma in the eligible eye(s) which could interfere with study interpretation~3. History of ocular surgery within 6 months of the Screening Visit, or any prior corneal refractive surgery in the eligible eye(s)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Once Daily Netarsudil Ophthalmic Solution (Type: EXPERIMENTAL): One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the evening for an 8 week period in up to 20 subjects.
- Twice Daily Netarsudil Ophthalmic Solution (Type: EXPERIMENTAL): One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the morning and in the evening for an 8 week period in up to 20 subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin AUC-10 With Early PET Scanning in Metastatic Seminoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Metastatic seminoma with International Germ Cell Consensus Classification (IGCCCG) good prognosis.~2. Glomerular filtration rate (GFR) by Ethylenediaminetetraacetic acid (EDTA) clearance over 25 ml/min.~3. Eastern Cooperative Oncology Group (ECOG) Performance status 0-3.~4. Normal Alpha-fetoprotein (All levels of Human chorionic gonadotropin and Lactate dehydrogenase are acceptable).~5. Males aged ≥18 and ≤75 years.~6. Able to give written informed consent prior to study entry.~7. Patients must be sterile or agree to use adequate contraception during the period of therapy.~Exclusion Criteria:~1. Metastatic seminoma with any non-pulmonary visceral metastases.~2. Raised Alpha-fetoprotein.~3. Any previous chemotherapy or radiotherapy.~4. Currently enrolled in any other investigational drug study.~5. Other malignancy except basal cell.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Carboplatin AUC-10 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* men or women aged over 18 years~* recipient of kidney transplant (planned in next 24 hours)~Exclusion Criteria:~* recipients of multi-organ transplant~* previous treatment with Campath-1H~* active infection (including HIV, hepatitis B or C)~* history of anaphylaxis to humanized monoclonal antibody~* history of malignancy (except adequately treated non-melanoma skin cancer)~* loss of kidney transplant within 6 months not due to technical reasons~* medical history that might limit the individual's ability to take trial treatments for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab/Sirolimus (Type: EXPERIMENTAL): Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus
- Alemtuzumab/Tacrolimus (Type: EXPERIMENTAL): Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus
- Basiliximab/Tacrolimus (Type: ACTIVE_COMPARATOR): Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus
- Basiliximab/Sirolimus (Type: ACTIVE_COMPARATOR): Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Center Study of New Medications to Treat Vaginal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:~* Capable of providing written informed consent or assent~* Currently not menstruating and not anticipating menses during treatment~* If heterosexually active, subject must be post-menopausal for ≥ 1 year, surgically sterile, or practicing an acceptable form of birth control~* Negative pregnancy test~* Other criteria as identified in the protocol~Exclusion Criteria:~* Other infectious causes of vulvovaginitis~* Subject has recently used, or is expected to require the concomitant use of prohibited medications/products~* Nursing mother~* Use of any investigational drug within 30 days of enrollment~* History of hypersensitivity to any ingredient/component of the formulations~* Other criteria as identified in the protocol

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terconazole vaginal gel (Type: ACTIVE_COMPARATOR): One applicator full at bedtime
- Metronidazole vaginal gel (Type: ACTIVE_COMPARATOR): One applicator full at bedtime
- Terconazole/metronidazole vaginal gel (Type: ACTIVE_COMPARATOR): One applicator full at bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has completed Protocol 137OB-201.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin B12 for Aromatase Inhibitors Musculoskeletal Symptoms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sign informed consent and Pain level \> 4 in the BPI scale,~* Stage I-III~Exclusion Criteria:~* \<18 yrs~* Stage IV~* BPI Score \<4~* Zubrod score \>2

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Oral Vitamin B12

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy overweight male and female participants~* Age 18-75 years~* BMI ≥25\<35 Kg/m2~Exclusion Criteria:~* Pregnancy/breast-feeding~* Allergy/Intolerance~* Anaemic participants: Hb \<10g/dL~* Diabetic participants: fasting blood glucose \>125 mg/dL~* Serum Aspartate Transaminase, Alkaline Phosphatase and Serum albumin level 3 times the upper limit of normal range~* Participants on other medications (lipid lowering drugs, oral hypoglycemics)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Test (Type: EXPERIMENTAL): Fibre rich Health Food Drink packed as 30g individual sachet, administered as a single serve in 200 mL of luke warm water
- Placebo (Type: PLACEBO_COMPARATOR): No Fibre Health Food Drink packed as 25g individual sachet, administered as single serve in 200 mL of luke warm water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Two through \<18 years of age at the time of first HAE attack.~   * Prepubertal and pubertal/postpubertal subjects experiencing and acute cutaneous, abdominal, or laryngeal HAE attack treated with icatibant as part of this study.~  * Pubertal/postpubertal subjects with HAE who are treated with icatibant, but not during an attack.~2. Documented diagnosis of HAE Type I or II.~3. Informed consent (and subject assent as appropriate) signed by the subject's parent(s)or legal guardian(s).~Exclusion Criteria:~1. Diagnosis of angioedema other than HAE.~2. Participation in another clinical trial that involves the use of any investigational product (drug or device)within 30 days prior to study enrollment or at any time during the study.~3. Any known factor/disease that might interfere with the treatment compliance, study conduct,or result interpretation.~4. Congenital or acquired cardiac anomalies that interfere significantly with cardiac function.~5. Treatment with ACE inhibitors within 7 days prior to treatment.~6. Use of hormonal contraception within the 90 days prior to treatment.~7. Androgen use (eg, stanozolol, danazol, oxandrolone, methyltestosterone, testosterone) within the 90 days prior to treatment.~8. Pregnancy or breastfeeding.~9. A physical condition that interferes with pubertal status determination.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Icatibant (Type: EXPERIMENTAL): Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Seropositive for HCMV IgG antibodies before transplantation~* First allogeneic Human blood precursor cell (HBPC) transplantation performed for 1 of the following diagnoses: leukaemia, lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorder~* Evidence of post transplantation engraftment~* Able to swallow tablets.~Exclusion Criteria:~* Previous anti-HCMV therapy after this allogeneic HBPC transplantation~* Mismatched or cord blood transplant recipients~* Current or history of end-organ HCMV disease~* Graft versus host disease (GVHD)~* Impaired liver function~* Reduced renal function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose regimen 1 (Type: EXPERIMENTAL): 60 mg AIC246, one tablet per day
- Dose regimen 2 (Type: EXPERIMENTAL): 120 mg AIC246, one tablet per day
- Dose regimen 3 (Type: EXPERIMENTAL): 240 mg AIC246, one tablet per day
- Placebo (Type: OTHER): Placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Ability of the participant's legally authorized representative (e.g. their parent or legal guardian) to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local participant privacy regulations.~* Weight \>=3.5 kg at the time of screening.~* Severe hemophilia A defined as less than (\<) 1 IU/dL (\<1%) endogenous FVIII documented in the medical record or as tested during the Screening Period.~Key Exclusion Criteria:~* Any exposure to blood components, factor VIII replacement products, including commercially available rFVIIIFc at any time prior to or during screening.~* History of positive inhibitor testing. A prior history of inhibitors was defined based on a patient's historical positive inhibitor test using the local laboratory Bethesda value for a positive inhibitor test (ie, equal to or above lower level of detection).~* History of hypersensitivity reactions associated with any rFVIIIFc administration.~* Other coagulation disorder(s) in addition to hemophilia A.~* Any concurrent clinically significant major disease that, in the opinion of the Investigator, would make the participant unsuitable for enrollment.~* Current systemic treatment with chemotherapy and/or other immunosuppressant drugs.~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- rFVIIIFc (Type: EXPERIMENTAL): Participants were to receive rFVIIIFc as follows- Prophylaxis regimen (PR): rFVIIIFc 25-80 international units per kilogram (IU/kg), at 3- to 5-day intervals until participant reached greater than or equal to (\>=) 50 exposure days (ED: 24-hour period in which \>=1 injection/dose of rFVIIIFc was given), or study withdrawal/end of study. Adjustments to dose/dosing interval was done as needed by investigator; Treatment with an optional ER (Episodic regimen) can be initiated before PR at investigators discretion; ITI: rFVIIIFc 200 IU/kg, daily for participants who, after exposure to rFVIIIFc, had positive high titer inhibitor (\>=5.00 Bethesda Units per milliliter \[BU/mL\]) or positive low titer inhibitor (\>=0.60 and \<5.00 BU/mL) and had poorly controlled bleeding despite increased rFVIIIFc doses, or required bypassing agent to treat bleeding.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Galantamine Effects in Patients With Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Diagnosis of Metabolic Syndrome based on recently established criteria (three abnormal findings of the following five)~  * Increased abdominal circumference ≥ 102 cm for men and 90 cm for women~ * Low plasma level of HDL cholesterol \< 40md/dL for men and 50 mg/dL for women~ * Increased values for plasma triglycerides \> 150 mg/dL~ * Elevated blood pressure ≥130/85 mmHg~ * Elevated level of blood sugar value to 100 mg/dL~* Body Mass Index (BMI) between 25 and 39, with weight maintenance diet and stable for at least 6 months before study entry~* Normal renal function and thyroid function~* Able to participate in the study by signing an informed consent form and comply with study stages throughout its duration~Exclusion:~* On use of antidiabetic medication~* Triglyceride levels ≥ 400 mg/dL or use of lipid lowering medication~* Levels of aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 200 U/L~* Levels of aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 200 U/L~* The office systemic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg at rest~* BMI ≥ 40kg/m²~* In use of antihypertensive drugs that interfere with the heart rate variability~* On the use of drugs that have known or probable interaction with galantamine: amitriptyline, fluoxetine, fluvoxamine, ketoconazole, oxybutynin, paroxetine, quinidine~* Already participant in regular exercise programs, defined as 90 minutes of activity per week~* Medical history, previous diagnosis or previous supplementary examinations indicating presence of cardiac arrhythmias, coronary artery disease, valvular disease, heart failure, chronic obstructive pulmonary disease, acute or chronic liver disease, renal insufficiency, thyroid disorders, chronic inflammatory diseases, cancer, positive status for HIV, other debilitating diseases~* Abuse of alcohol or other substances in the 12 months prior to study entry~* History of major depression or patients with suicidal ideation~* Personal history of eating disorder~* Utilization of drugs for obesity~* Use of serotonin reuptake inhibitors~* Pregnancy or desire to become pregnant during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Galantamine (Type: EXPERIMENTAL): * 8 mg of Galantamine for 4 weeks~* 16 mg Galantamine for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): * 8 mg of placebo for 4 weeks~* 16 mg placebo for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Physiological Study of Human Cholesterol Metabolism and Excretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aim II. 100 subjects aged 30-80 with stable medical and/or surgical illnesses.~* Aim III. 30 subjects age 18-80 with LDL cholesterol \<190, fasting triglycerides\<250 and stable medical or surgical illnesses.~Exclusion Criteria:~* Aim II. Subjects taking ezetimibe, bile acid sequestrants or with gastrointestinal or liver disease will be excluded since these may affect whole body cholesterol metabolism.~* Subjects with coronary heart disease or other medical illnesses will not be excluded if medically stable.~* Adults under age 30 and children will be excluded because in our current database there is no relation between carotid intima-media thickness and cardiovascular risk factors in this younger group.~* Aim III. Individuals have risk factors for coronary heart disease that mandate drug treatment according to the National Cholesterol Education Program guidelines will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Observational Arm (Type: NO_INTERVENTION): Cholesterol metabolic parameters will be measured in 100 subjects in an observational study. Results will be related to circulating biomarkers and carotid intima-media thickness.
- Ezetimibe Interventional Arm (Type: PLACEBO_COMPARATOR): Cholesterol metabolic parameters will be measured before and after ezetimibe or placebo intervention. Changes due to ezetimibe will be determined

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Requires IV antibiotic therapy with diagnosis of ventilated nosocomial pneumonia~* Gram-positive bacteria on respiratory Gram stain~Exclusion Criteria:~* Pneumonia of community, viral, fungal or parasitic etiology~* Structural lung abnormalities~* Immunosuppression~* Previous antibiotics for \> 24 hours~* Expected survival of \< 72 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tedizolid phosphate IV (Type: EXPERIMENTAL): Ventilated HABP/VABP participants receive tedizolid phosphate 200 mg IV once daily for 7 days, or for 14 days for concurrent bacteremia.
- Linezolid IV (Type: ACTIVE_COMPARATOR): Ventilated HABP/VABP participants receive linezolid 600 mg IV every 12 hours for 10 days, or for 14 days for concurrent bacteremia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete